Estradiol vs. Estrogen for Clinical Use

Introduction to Estradiol

The American College of Cardiology recommends transdermal 17β-estradiol as the preferred form of estrogen for clinical use due to its superior safety profile and physiological benefits compared to other estrogen formulations 1

Transdermal 17β-estradiol is the preferred route of administration as it mimics physiological serum estradiol concentrations and provides a better safety profile than oral formulations 1
Natural 17β-estradiol has less impact on coagulation, fibrinolysis markers, and blood pressure compared to synthetic estrogens like ethinyl estradiol 2
Transdermal 17β-estradiol avoids the hepatic first-pass effect, minimizing the impact on hemostatic factors 1
For systemic hormone replacement therapy, transdermal 17β-estradiol is recommended at doses of 50-100 micrograms daily 3

Transdermal 17β-estradiol has a more beneficial profile on circulating lipids, markers of inflammation, and blood pressure compared to other estrogen formulations 1
It is more effective in achieving peak bone mineral density and reducing bone resorption markers compared to ethinyl estradiol-based combined oral contraceptives 1

For patients with Premature Ovarian Insufficiency (POI), transdermal 17β-estradiol is strongly recommended as the first choice, particularly in cancer survivor girls 4
Oral 17β-estradiol should only be administered when contraindications for transdermal route exist (poor compliance, chronic skin conditions) 4
For pubertal induction in girls with POI, transdermal 17β-estradiol has shown better results in terms of uterine parameters compared to ethinyl estradiol 4

Estrogen-only therapy is specifically recommended for women who have had a hysterectomy due to its more favorable risk/benefit profile 3
Women without a uterus do not need progestogen, making estradiol-only therapy appropriate 3

Estrogen doses should be increased gradually over time, with clinical assessment guiding dose escalation 4

Estrogen therapy, including topical, remains contraindicated in women with a history of hormone-sensitive cancers, particularly breast cancer 3

Avoiding transdermal estrogen due to unfounded safety concerns is not recommended, as it has an excellent safety profile for appropriate patients 3
Not considering the type of estrogen (natural vs. synthetic) when evaluating potential side effects 2
Failing to recognize that approximately 20 micrograms of ethinyl estradiol is equivalent to 2 mg of estradiol valerate in terms of hormonal effect 2